Drug reference
eribulin
Microtubule inhibitor · Antineoplastic
Microtubule inhibitorAntineoplastic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Eribulin is a synthetic analogue that binds to the vinca site on β-tubulin and inhibits microtubule assembly. It is a poorer substrate than other microtubule disruptors for the P-glycoprotein (Pgp) efflux pump.
Indications
Drug-resistant metastatic breast cancerLiposarcoma
Side effects
Common
NeutropeniaNeuropathiesGastrointestinal toxicities
Related guidelines
Ask House about eribulin
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team